Kevin Lokay serves as Independent Director of the Company. Mr. Lokay is Head of U.S. Immuno-Oncology Franchise at AstraZeneca plc, a pharmaceutical company, a position he has held since November 2019, prior to which he was Head of U.S. Lung Cancer Franchise from August 2018. Mr. Lokay served as an advisor to AbbVie Inc., a pharmaceutical company, from August 2017 until December 2017. Mr. Lokay was previously Vice President and Business Unit Head, Oncology at Boehringer Ingelheim, a pharmaceutical company, a position he held from December 2009 until December 2016. Prior to joining Boehringer Ingelheim, he was President and Chief Executive Officer of Cytogen Corporation from 2007 until 2008 and served in various positions at GlaxoSmithKline from 1997 until 2007 and at Merck & Co. from 1981 until 1997. Mr. Lokay received a B.A. in Economics from Lafayette College and a M.S. from Purdue University.
As the Independent Director of Galera Therapeutics Inc, the total compensation of Kevin Lokay at Galera Therapeutics Inc is $134,167. There are 11 executives at Galera Therapeutics Inc getting paid more, with J. Mel Sorensen having the highest compensation of $2,465,100.
Kevin Lokay is 63, he's been the Independent Director of Galera Therapeutics Inc since 2019. There are 6 older and 9 younger executives at Galera Therapeutics Inc. The oldest executive at Galera Therapeutics Inc is Joel F. Sussman, 72, who is the Chief Accounting Officer & Treasurer.
Kevin's mailing address filed with the SEC is C/O GALERA THERAPEUTICS, INC., 45 LIBERTY BLVD #230, MALVERN, PA, 19355.
Over the last 5 years, insiders at Galera Therapeutics Inc have traded over $19,201,067 worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth $29,883,202 . The most active insiders traders include Holdings A/S Novo, Group Inc Blackstone Group ... и Bioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of $11,809. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth $4,691.
galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.
Galera Therapeutics Inc executives and other stock owners filed with the SEC include: